Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines Guidelines


Authors: Sanchorawala, V.; Boccadoro, M.; Gertz, M.; Hegenbart, U.; Kastritis, E.; Landau, H.; Mollee, P.; Wechalekar, A.; Palladini, G.
Title: Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines
Abstract: AL amyloidosis is a systemic amyloidosis and is associated with an underlying plasma cell dyscrasia. High dose intravenous melphalan and autologous stem cell transplantation was developed for the treatment of AL amyloidosis in the early 1990s and was prompted by its success in multiple myeloma. This application has evolved significantly over the past three decades. These guidelines provide a comprehensive assessment of eligibility criteria, stem cell collection and mobilisation strategies and regimens, risk-adapted melphalan dosing, role for induction and consolidation therapies, specific supportive care management, long-term outcome with respect to survival, haematologic response and relapse and organ responses following stem cell transplantation. These guidelines are developed by the experts in the field on behalf of the stem cell transplant working group of the International Society of Amyloidosis (ISA) and European Haematology Association (EHA). © 2021 Informa UK Limited, trading as Taylor & Francis Group.
Keywords: treatment outcome; patient selection; neoplasm recurrence, local; melphalan; amyloidosis; stem cell transplantation; hematopoietic stem cell transplantation; tumor recurrence; transplantation, autologous; supportive care; complication; autotransplantation; procedures; al amyloidosis; humans; human; immunoglobulin light-chain amyloidosis
Journal Title: Amyloid
Volume: 29
Issue: 1
ISSN: 1350-6129
Publisher: Taylor & Francis Group  
Date Published: 2022-01-01
Language: English
DOI: 10.1080/13506129.2021.2002841
PUBMED: 34783272
PROVIDER: scopus
DOI/URL:
Notes: Article -- Export Date: 1 April 2022 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Heather Jolie Landau
    419 Landau